Comparative study of self-report scales in cancer patients undergoing oral antineoplastic medications such as tyrosine kinase inhibitors
Not Applicable
- Conditions
- Adverse eventsD27.505.954.248
- Registration Number
- RBR-10myxdss
- Lead Sponsor
- niversidade Federal de São Paulo
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- Not specified
- Target Recruitment
- Not specified
Inclusion Criteria
older than 18 years; being treated with TKI alone as anticancer therapy, orally and for 3 months or more; being diagnosed with one of three cancers: kidney, lung, or chronic myeloid leukemia; Performance status between 0 and 2, evaluated according to the Eastern Cooperative Oncologic Group – ECOG scale
Exclusion Criteria
multiple comorbidities (3 or more), partial completion of one of the data collection instruments
Study & Design
- Study Type
- Intervention
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Assess therapeutic adherence through the measures of adherence to treatments questionnaire that will be answered in the four moments of medical consultation. We will look for associations between independent, sociodemographic and clinical variables, and dependent variables, treatment adherence and prevalent symptoms with degrees of severity.
- Secondary Outcome Measures
Name Time Method Evaluate the acceptability of the participant regarding the use of patient-reported outcomes version of the common terminology criteria for adverse events, through an acceptability questionnaire, where the acceptability percentages will be sought;To assess the feasibility of implementing the patient-reported outcomes version of the common terminology criteria for adverse events from the perspective of oncologists